EGRX
Healthcare · Drug Manufacturers - Specialty & Generic
Performance
EGRX (EGRX) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
EGRX (EGRX) operates in the Drug Manufacturers - Specialty & Generic space within the Healthcare sector. With a market cap of $3M, it qualifies as a small-cap company. Revenue has been contracting year-over-year, a headwind that investors will watch closely in upcoming earnings.
- Low P/E of 1.6× suggests the stock may be undervalued relative to earnings
- Forward P/E (0.1×) is lower than trailing P/E (1.6×) — analysts expect earnings to improve
- Current ratio of 2.2× — ample short-term liquidity
- Price is near its 52-week low — potential entry point with asymmetric upside
- Low beta of 0.66 — less volatile than the market, suitable for conservative portfolios
- Revenue declined 13% YoY — warning sign for business momentum
- Thin profit margin of 4.6% — little buffer against cost increases
- High debt-to-equity of 28.75× increases financial risk, especially with elevated interest rates
- No dividend history — total return depends entirely on price appreciation
Verdict
Buy / Hold
More positives than negatives. Fundamentals support holding while monitoring key risks.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
This stock does not pay dividends.
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
EPS (TTM)
$0.16
P/E (TTM)
1.6
Fwd P/E
0.1
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $0.25
Graham Number
√(22.5 × EPS × Book Value)
$8.32
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
N/A
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
2/10
29% score
Pays dividends
No dividend history found
Dividend consistency (5Y+)
Uninterrupted dividend payments for at least 5 years
ROE above 10%
4.9%Return on equity — measures how efficiently capital is used
Positive profit margin
4.6%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
-12.8%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
28.75×Low financial leverage reduces risk of distress
Current ratio above 1
2.16×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$0K/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
Stock must distribute income to shareholders
Related Assets
Healthcare
About EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Location
Woodcliff Lake, United States
Employees
134